Shionogi, Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1919-01-01

Employees: -

Market Cap: $13.1B

Website: https://www.shionogi.com/jp/ja/

Clinical Trials

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants

Phase 2

Completed

Conditions: Hospital Acquired Pneumonia (HAP)
Complicated Urinary Tract Infection (cUTI)
Sepsis
Ventilator-acquired Pneumonia
Bloodstream Infections (BSI)
Complicated Intra-abdominal Infection (cIAI)
Gram-negative Bacterial Infections

Interventions: Drug: Cefiderocol
Drug: Standard of Care

First Posted Date: 2020-04-06

Last Posted Date: 2024-01-24

Lead Sponsor: Shionogi

Target Recruit Count: 54

Registration Number: NCT04335539

Locations: 🇱🇻
Bernu Kliniska Universitates Slimnica Childrens Hospital - Tornakalna, Riga, Latvia
🇪🇪
Tartu Ulikooli Kliinikum - Anestesioloogia ja Intensiivravi Kliinik, Tartu, Estonia
🇬🇪
JSC "Medical Corporation Evex" " M. Iashvili Batumi Maternal and Child Central Hospital", Batumi, Georgia

and more 20 locations

First-in-human Study of S-588210 (S-488210+S-488211)

Phase 1

Completed

Conditions: Lung Cancer
Mesothelioma
Head and Neck Cancer
Bladder Cancer
Esophageal Cancer

Interventions: Biological: S-488210
Biological: S-488211

First Posted Date: 2020-03-20

Last Posted Date: 2022-01-26

Lead Sponsor: Shionogi

Target Recruit Count: 10

Registration Number: NCT04316689

Locations: 🇬🇧
University College London Clinical Research Facility, London, United Kingdom

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

Phase 2

Completed

Conditions: Hospital Acquired Bacterial Pneumonia (HABP)
Ventilator Associated Bacterial Pneumonia (VABP)
Gram-negative Bacterial Infections
Complicated Urinary Tract Infection (cUTI)

Interventions: Drug: Cefiderocol
Drug: Standard of Care

First Posted Date: 2020-01-02

Last Posted Date: 2024-11-18

Lead Sponsor: Shionogi

Target Recruit Count: 85

Registration Number: NCT04215991

Locations: 🇺🇸
University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States
🇬🇪
JSC "EVEX Medical Corporation"- M Lashvili Childrens Central Hospital, Tbilisi, Georgia
🇬🇪
Ltd Unimedi Kakheti Childrens New Clinic, Tbilisi, Georgia

and more 22 locations

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: S-648414
Drug: Midazolam
Drug: Dolutegravir

First Posted Date: 2019-11-01

Last Posted Date: 2021-11-01

Lead Sponsor: Shionogi

Target Recruit Count: 98

Registration Number: NCT04147715

Locations: 🇯🇵
P-One Clinic, Hachioji City, Toyko, Japan
🇺🇸
PPD Ph 1 Clinical Research Unit, Austin, Texas, United States

Evaluation of S-600918 in Adults With Refractory Chronic Cough

Phase 2

Completed

Conditions: Chronic Cough

Interventions: Drug: S-600918
Drug: Placebo to S-600918

First Posted Date: 2019-10-01

Last Posted Date: 2024-03-27

Lead Sponsor: Shionogi

Target Recruit Count: 406

Registration Number: NCT04110054

Locations: 🇺🇸
Research Solutions of Arizona, Litchfield Park, Arizona, United States
🇺🇸
Allergy & Asthma Associates of Southern California dba Southern California Research, Mission Viejo, California, United States
🇺🇸
Medical Research Of Central Florida, LLC, Leesburg, Florida, United States

and more 132 locations

Effect of Food and Calcium on Pharmacokinetics of a Single Dose of S-888711 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: S-888711
Dietary Supplement: Calcium Antacid

First Posted Date: 2019-04-01

Last Posted Date: 2019-04-01

Lead Sponsor: Shionogi

Target Recruit Count: 15

Registration Number: NCT03897413

Locations: 🇺🇸
Healthcare Discoveries, LLC, San Antonio, Texas, United States

Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia

Phase 1

Terminated

Conditions: Bacterial Pneumonia

Interventions: Drug: Cefiderocol
Drug: Standard of Care Antibiotic

First Posted Date: 2019-03-05

Last Posted Date: 2020-11-05

Lead Sponsor: Shionogi

Target Recruit Count: 7

Registration Number: NCT03862040

Locations: 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
North Western University, Chicago, Illinois, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States

and more 4 locations

Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

Conditions: Bacterial Infections

First Posted Date: 2018-12-19

Last Posted Date: 2020-02-28

Lead Sponsor: Shionogi

Registration Number: NCT03780140

A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder

Phase 3

Terminated

Conditions: Depressive Disorder

Interventions: Drug: Duloxetine Hydrochloride

First Posted Date: 2018-01-10

Last Posted Date: 2021-06-18

Lead Sponsor: Shionogi

Target Recruit Count: 151

Registration Number: NCT03395353

Locations: 🇯🇵
Shionogi, Osaka, Japan

A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder

Phase 3

Completed

Conditions: Depressive Disorder

Interventions: Drug: Duloxetine Hydrochloride
Drug: Placebo

First Posted Date: 2017-10-20

Last Posted Date: 2021-01-05

Lead Sponsor: Shionogi

Target Recruit Count: 149

Registration Number: NCT03315793

Locations: 🇯🇵
Shionogi, Osaka, Japan

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy